Financial Performance - Aligos reported a net loss of (3.07), compared to a net loss of (10.37) per share in Q3 2023[7]. - Cash, cash equivalents, and investments totaled 135.7 million as of December 31, 2023, indicating a decrease of approximately 44.8%[6]. - Total operating expenses for Q3 2024 were 22.3 million in Q3 2023, indicating a slight decrease[15]. - Aligos believes its current cash balance is sufficient to fund planned operations through the end of 2025[6]. Research and Development - Research and development (R&D) expenses increased to 15.9 million in Q3 2023, primarily due to higher third-party expenses for clinical trials[8]. - Aligos is progressing ALG-000184 for chronic hepatitis B (CHB) towards a Phase 2 study next year, with positive feedback from the FDA regarding its primary efficacy endpoint[3]. - The company expects to begin externally funded clinical studies for ALG-097558 in COVID subjects later this year, with three additional clinical studies planned for 2024[5]. Clinical Trial Results - The company announced positive topline HERALD data for ALG-055009, showing placebo-adjusted median relative reductions in liver fat of up to 46.2%[2]. - Up to 70% of subjects treated with ALG-055009 achieved a ≥30% relative reduction in liver fat compared to baseline[4]. General and Administrative Expenses - General and administrative (G&A) expenses decreased to 6.4 million in Q3 2023, reflecting a reduction in third-party expenses including legal costs[9].
Aligos Therapeutics(ALGS) - 2024 Q3 - Quarterly Results